| Position£ºzensun.com - Products - Recombinant Human ErbB3 Fragment (rhErbB3-f) |
| Therapeutic cancer vaccine: recombinant human ErbB3 fragment (rhErbB3-f) immunization |
rhErbB3-f is a recombinant human ErbB3 receptor fragment produced by expression in E. coli. After purification and formulation with adjuvant, it can be used for immunization to induce the production of specific anti-ErbB3 antibodies for the treatment of patient with breast cancer characterized by the overexpression of ErbB2. rhErbB3-f, therefore, is as a therapeutic cancer vaccine.
|
| Drug Mechanisms |
| Signaling via the ErbB receptor family has significant effects on the important biological process, such as cell growth, differentiation and movement. |
Zensun has discovered through its research that the ErbB3 molecule is a new target for cancer therapy. It has also been demonstrated that heterodimerization of ErbB2 with ErbB3 is essential for tumor development. Based on these insights, rhErbB3-f, a therapeutic tumor vaccine, has been developed.
|
Indications |
| 1. Early, intermediate, advanced and postoperative breast cancer characterized by overexpression of ErbB2. |
| 2. High-risk individuals with a family history of breast cancer. |
3. Ovarian cancer, colon cancer, lung cancer and prostate cancer in which the tumors overexpress ErbB2.
|
| Pharmacological Action |
| Results of animal experimentation have shown that vaccination with rhErbB3-f delays the occurrence of spontaneous breast cancer tumors in FVB/N neu transgenic mice and inhibits the development of the tumors, effectively arresting the growth of in situ transplanted breast in this animal model. Moreover, anti-rhErbB3-f polyclonal antibodies can directly inhibit transplanted breast tumors in nude mice and inhibit in vitro cell growth. Vaccination of mice with recombinant mouse ErbB3 fragment also inhibits the growth of in situ transplanted breast cancer cells in FVB/N neu transgenic mice, indicating that immune tolerance can be overcome. |
Thus, the main pharmacological action is through the induction of specific anti-ErbB3 antibodies, which effect tumor cell growth inhibition. |
Safety |
No adverse side effects or autoimmune responses associated with the drug have been observed in detailed safety pharmacology, acute toxicity, and long term toxicity studies in mice or monkeys.
|
Comparison of antibody therapy vs. vaccine therapy |
|
| |
RhErbB3-f |
Herceptin
(humanized antibody)
|
| Mechanism |
Specific active
immunity |
Specific passive immunity |
| Indications |
Breast cancer with ErbB2 overexpression |
Breast cancer with ErbB2 overexpression |
| Side effects |
No side effects found in either animal experiments or Phase I clinical trial |
28% patients develope severe heart failure if used in combination with adriamycin |
| Expressive system |
Bacteria |
CHO |
| Price |
RMB10-15k per year |
RMB100-200k per year |
|
 |
| |
 |
| |
 |
| |
| |
| |
